ArticleFrontiers in cardiovascular medicine2026
Lp(a), platelet count, aspirin and cardiovascular outcome: a prospective cohort analysis.
Article in Frontiers in cardiovascular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Elevated lipoprotein(a) [Lp(a)] and increased platelet count independently predict major adverse cardiovascular events (MACE), yet their interplay and joint value in cardiovascular risk stratification remain incompletely elucidated. We examined their separate and joint associations with incident MACE, with a secondary exploratory analysis of whether preventive benefit from aspirin differs across biomarker-defined subgroups. Methods and results: We included 250,927 participants free of prior cardiovascular disease (CVD) from the UK Biobank (enrolled 2006-2010). Participants were categorized into four groups based on Lp(a) status (elevated: >125 nmol/L) and platelet count (increased: upper tertile, >273 × 10 Conclusion: Concomitant elevation of Lp(a) and platelet count identifies a subgroup of individuals at substantially higher risk for MACE. The observed potential benefit of aspirin in the double-high subgroup is exploratory and warrants further prospective investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.